Evidence for separate neuronal mechanisms for the discriminative stimulus and catalepsy induced by delta 9-THC in the rat.
W R Prescott, L H Gold, B R Martin
Psychopharmacology 1992 DOI: 10.1007/bf02244975 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | delta 9-THC anticholinergic pretreatment naloxone |
| Topics | Cannabis |
| Key findings | Delta 9-THC produced discriminative stimulus effects at an ED50 of 0.8 mg/kg and catalepsy at 4.0 mg/kg, with similar time courses. Catalepsy was not attenuated by long-term low-dose exposure. Anticholinergic pretreatment eliminated catalepsy but not discriminative stimulus effects, indicating distinct mechanisms for these cannabinoid-induced behaviors. |
Abstract
The cataleptogenic effect of delta 9-THC was compared to its discriminative stimulus effects in rats. The ED50s for the discriminative stimulus and catalepsy were 0.8 and 4.0 mg/kg, respectively, while their time courses were very similar. The ED50 of delta 9-THC for catalepsy in experimentally naive rats was not different from that in rats trained with the drug discrimination procedure, indicating that the cataleptogenic effect was not appreciably attenuated by long-term exposure to low doses of delta 9-THC. Pharmacologically, the catalepsy produced by delta 9-THC more closely resembled that of haloperidol than of morphine, since anticholinergic pretreatment eliminated the delta 9-THC-induced catalepsy while pre-treatment with naloxone had no effect. Although the cataleptogenic effect of delta 9-THC could be pharmacologically manipulated by anticholinergic pre-treatment, its discriminative stimulus effects were not changed in the same animals. These results demonstrate that distinctive mechanisms of action exist for these cannabinoid-induced behaviors.
Comparable studies
Other preclinical and animal studies on cannabis, most cited first.
Citations in the library
Cited by 7
- Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users? Neurotoxicity Research November 1, 2016
- Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans. The International Journal of Neuropsychopharmacology October 2012
- Enhancement of the behavioral effects of endogenous and exogenous cannabinoid agonists by phenylmethyl sulfonyl fluoride. Neuropharmacology February 2012
- Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats. Psychopharmacology June 2005
- (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology August 2001
and 2 more in the library
Cites 4
- Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences March 1990
- Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology November 1, 1988
- Pharmacological potency of R- and S-3'-hydroxy-delta 9-tetrahydrocannabinol: additional structural requirement for cannabinoid activity. Pharmacology, Biochemistry, and Behavior July 1984
- Delta 9-Tetrahydrocannabinol, ethanol, and amphetamine as discriminative stimuli-generalization tests with other drugs. Psychopharmacologia April 15, 1976